Search results
131 Results for 'David J. Mooney'
- Technologies (16)
- Collaborations (1)
- Team (0)
- News (84)
- Pages (0)
- Multimedia (20)
- Publications (0)
- Jobs (0)
- Events (10)
Technologies 16
-
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
Tunable ECMs for more effective T cell therapies
Tunable hydrogels that enhance the efficacies of adoptively transferred immune cells during their manufacturing by mimicking target tissue biomechanics. -
Soft hydrogel electrodes for better, safer implants
Soft, conductive hydrogels match the physical properties of the human brain, enabling the creation of electrodes and implantable devices that can improve brain-machine interfaces while reducing the risk of injury. -
FeCILL: Targeted Treatment for Severe Fungal Infections
FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections. -
Sustained Growth Factor Delivery for Regenerating Tissues
The Problem Millions of people worldwide suffer from traumatic injuries or health conditions that cause damage to soft tissues including nerves, muscles, and blood vessels. The body can heal some of that damage, but more serious cases like the severing of a nerve or sustained oxygen deprivation can lead to permanent loss of movement or... -
Single-Cell Encapsulation for Improved Cell Therapies
The Problem Mesenchymal stromal cells (MSCs) are valued for their ability to secrete compounds that modulate the body’s immune system, making them an attractive solution for existing problems with cell therapies including host-vs-graft disease and organ transplant rejections. However, MSCs are rapidly cleared from the body and can come under fire from the immune system....
Collaborations 1
i3 Center: Biomaterials to Create T Cell ImmunityNews 84
Multimedia 20
-
Video/AnimationFeCILL: Reimagining How We Treat the Sickest PatientsOpportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute... -
Video/AnimationMetabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokinesThis animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University
-
Audio/PodcastImmunoengineering with Dave Mooney – BIOS PodcastWyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They... -
Video/AnimationJanus Tough Adhesives for Tendon RepairThere is a large unmet need for tendon regeneration therapies after injury. Building upon the tough gel adhesive technologies developed at the Wyss Institute at Harvard University and the Harvard School of Engineering and Applied Sciences, researchers from these institutions collaborated with a group at Novartis to create the Janus Tough Adhesives (JTAs). This two-sided... -
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University. -
Video/AnimationAlginate Hydrogel for AngiogenesisThis video describes how an alginate hydrogel can be used to trigger the formation of new blood vessels at an ischemic site in the body. Credit: Wyss Institute at Harvard University.
Events 10
-
May 17, 2021, 1:00pm - 5:00pmSymposium
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Cancer immunotherapy has emerged as a major component of cancer treatment. This symposium aims to catalyze new approaches to anti-cancer immunity in settings where it is currently limited by bringing together bioengineers, cancer immunologists, and oncologists. Featured topics Mechanisms of Protective Tumor Immunity Glenn Dranoff, M.D. Novartis Single-cell sequencing of T cells in food... Free and open to public -
Mar 25, 2021, 4:00pm - 5:00pmWyss Event
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
This talk will highlight tissue engineering strategies using biologics, cellular and gene therapeutics that are now beginning to enter the clinical arena. These technologies include the use of 3D printing on growth factors to rebuild tissues around teeth and replacements in the jaws, such as dental implants. Free and open to public -
Apr 22 → 23, 2020
Symposium
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Join and hear from keynote speakers David Mooney of the Wyss Institute at Harvard University and Melody Swartz of the Pritzker School of Molecular Engineering at University of Chicago along with graduate student presentations in the field of regenerative medicine and transplant. Symposium e-booklet will be sent prior to the event to those registered. The theme... Free and open to public